Compare UTL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | PCRX |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 1.1B |
| IPO Year | 1995 | 2010 |
| Metric | UTL | PCRX |
|---|---|---|
| Price | $53.17 | $24.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $56.50 | $30.25 |
| AVG Volume (30 Days) | 85.8K | ★ 399.9K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 1.37 | ★ 107.44 |
| EPS | ★ 2.11 | 0.19 |
| Revenue | $536,000,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $5.43 | $6.78 |
| Revenue Next Year | $4.22 | $8.54 |
| P/E Ratio | ★ $24.87 | $128.71 |
| Revenue Growth | 8.33 | ★ 26.04 |
| 52 Week Low | $45.17 | $18.80 |
| 52 Week High | $57.26 | $27.66 |
| Indicator | UTL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 42.74 |
| Support Level | $52.10 | $21.97 |
| Resistance Level | $53.80 | $26.93 |
| Average True Range (ATR) | 0.99 | 0.70 |
| MACD | -0.14 | -0.20 |
| Stochastic Oscillator | 20.25 | 24.69 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.